Outsourcing in Clinical Trials Europe 201421-22 May 2014, Brussels, Belgium
The OCT team would like to thank you for making the 2013 event such a huge success.
Earlier this year 250 industry professionals attended OCT Europe to learn from case-study based presentations, network with their peers, discover new solutions and services and find answers to all of their clinical outsourcing challenges.
Covering all aspects of clinical outsourcing from informed sourcing and efficient contract negotiation through to effective management, monitoring and communication techniques, this year’s agenda boasted presentations, case studies, panel discussions and roundtables all presented and facilitated by a high calibre speaking faculty from across Europe.
The Outsourcing Clinical Trial series is growing every year. View the full list of upcoming events to make sure you don’t miss any news. The list of websites will be updated as soon as new events are live so check back regularly
We are always happy to see photos taken at our events! If you have any you would like to submit, please email email@example.com The Arena Team
Contract Research Organization, Clinovo tells us about their experience and takeaways from Outsourcing in Clinical Trials Southern California.
Primary delegates for this event are those with responsibility for clinical outsourcing decisions and strategy within pharmaceutical, biotechnology, and virtual companies across Europe:CEOCMOCSOCFO
Outsourcing in Clinical Trials East Coast boasts a fantastic exhibition of outsourcing service providers and industry specialists. Our exhibition area is already filling up due to the fantastic event which took place at earlier this year.
Our production team will soon begin research to develop the 2014 agenda. Catering both to small to mid-sized biotech and pharma as well as the larger companies, this 2014 event will include a stream which offers content relevant to the company types separately.
OncoMed Pharmaceuticals has initiated a Phase Ib clinical trial of its Wnt-pathway-targeting antibody vantictumab (OMP-18R5) in combination with nab-paclitaxel (Abraxane) and gemcitabine in patients with Stage IV pancreatic cancer.
French pharmaceutical firm Sanofi has released results of a 24-week Phase IIIb clinical trial showing that Lyxumia (lixisenatide) met the primary endpoint of non-inferiority in blood sugar lowering (HbA1c) when given to patients either before breakfa…
US-based biopharmaceutical firm Lexicon Pharmaceuticals has released top-line results from an initial Phase II trial, designed to assess the use of its investigational drug LX1033 in diarrhea-predominant irritable bowel syndrome (IBS-d).
US-based biopharmaceutical firm Puma Biotechnology has released top line results from the I-SPY 2 Trial ('Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2') of its investigational drug PB272 (…
US-based biopharmaceutical firm Exelixis has started a Phase II clinical trial of cabozantinib plus abiraterone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer (CRPC).